FDA Adverse Event Injury Summary report: N

XEN 45 GTS

MDR report key: 8294864 · Received January 31, 2019

Report

Report Number
3011299751-2019-00025
Event Type
Injury
Date Received
January 31, 2019
Date of Event
December 15, 2018
Report Date
March 29, 2019
Manufacturer
ALLERGAN (IRVINE)
Product Code
KYF
PMA / PMN Number
K161457
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
UK
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 0

A REVIEW OF THE DEVICE HISTORY RECORD HAS BEEN INITIATED. IF ANY DEVIATIONS OR NON-CONFORMANCES ARE FOUND, A SUPPLEMENTAL MEDWATCH WILL BE SUBMITTED.

Description of Event or Problem · 0

REPORTED EVENTS OF DELAYED SUPRACHOROIDAL BLEEDING (SCH) AND POTENTIALLY "KISSING" CHOROIDAL TOUCH DUE TO SIGNIFICANT DELAYED SCH IN THE LEFT EYE WERE NOTED IN THE ARTICLE "MANAGING DELAYED SUPRACHOROIDAL HEMORRHAGE AFTER INSERTION OF XEN45 GLAUCOMA DEVICE." JOURNAL OF GLAUCOMA, DECEMBER 2018, P.1-11.

Additional Manufacturer Narrative · 1

STRINGA, FRANCESCO, ET AL. "MANAGING DELAYED SUPRACHOROIDAL HEMORRHAGE AFTER INSERTION OF XEN45 GLAUCOMA DEVICE." JOURNAL OF GLAUCOMA, DECEMBER 2018, P.1-11. THE EVENT OF CHOROIDAL HEMORRHAGE IS A PHYSIOLOGICAL COMPLICATION AND ANALYSIS OF THE DEVICE GENERALLY DOES NOT ASSIST ALLERGAN IN DETERMINING A PROBABLE CAUSE FOR THIS EVENT. MULTIPLE REQUESTS FOR FURTHER INFORMATION HAVE BEEN MADE. ALLERGAN HAS RECEIVED NO RESPONSE FROM THE AUTHORS. DEVICE LABELING: THIS IS A KNOWN POTENTIAL ADVERSE EVENT ADDRESSED IN THE PRODUCT LABELING.

Description of Event or Problem · 1

REPORTED EVENTS OF DELAYED SUPRACHOROIDAL BLEEDING (SCH) AND POTENTIALLY "KISSING" CHOROIDAL TOUCH DUE TO SIGNIFICANT DELAYED SCH IN THE LEFT EYE WERE NOTED IN THE ARTICLE "MANAGING DELAYED SUPRACHOROIDAL HEMORRHAGE AFTER INSERTION OF XEN45 GLAUCOMA DEVICE." JOURNAL OF GLAUCOMA, DECEMBER 2018, P.1-11.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
88004 XEN 45 GTS IMPLANT, EYE VALVE KYF ALLERGAN (IRVINE) 61290

Patients

Seq Age Sex Outcome Treatment
1 78 YR Required Intervention